
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's sales experienced a remarkable growth of 29%, reaching $803 million in 2024, with management projecting revenues in the range of $940 to $955 million for the upcoming year. The company's strategic focus on cardiopulmonary solutions and neuromodulation devices positions it favorably within the healthcare market, with an impressive reliance on the U.S. market, which constitutes approximately half of its total revenue. Additionally, projections for the aura6000 device indicate a potential increase in market share, contributing to anticipated sales growth from $30 million in 2027 to $70 million by 2029, further underscoring the company's positive growth trajectory.
Bears say
LivaNova faces a potential slowdown in revenue growth, with expectations of low-single-digit increases primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. The company is also experiencing operating margin contraction and is projected to report earnings below consensus estimates, further contributing to a bearish outlook. Additionally, there are significant risks associated with the approval of new products and growth expectations in its core markets, which may further hinder financial performance.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares